Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abicipar pegol PK and Safety in Japanese AMD Patients (PINE)
NCT03335852Phase 1Completed
- Sponsor
- Allergan
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abicipar pegol in neovascular age-related macular degeneration (NVAMD), sponsored by Allergan. Primary endpoints: Peak Serum Concentration at 20 weeks, Serum Concentration Immediately before Next Dose at 20 weeks and 4 more. Started Nov 2017; status: completed.
02
Drugs
abicipar pegol
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03335852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03335852.